Search
Search
Editorially independent content, supported with advertising
08.20.21
If new treatment options for wet AMD are approved for treatment, retina specialists will have even more options to switch patients to a new therapy. Which drug candidates have phase 3 data and real-world data that could point toward upcoming action by regulatory bodies? Arshad M. Khanani, MD, MA (United States), convenes an international panel comprised of Justus G. Garweg, MD (Switzerland), Seenu M. Hariprasad, MD (United States), and Peter Kertes, MD, FRCSC (Canada), to review data related to brolucizumab (Beovu, Novartis), the Port Delivery System with Ranibizumab (Genentech), and faricimab (Roche). This editorially independent podcast is supported with advertising.
03.24.22
Art of Drug Choice: Treating New Wet AMD PatientsArshad M. Khanani, MD, MA; Lejla Vajzovic, MD, and Joseph M. Coney, MD
03.17.22
Art of Drug Choice: Who Is Best Suited for Extended-duration Therapy?Arshad M. Khanani, MD, MA; Lejla Vajzovic, MD; and Joseph M. Coney, MD
03.03.22
Art of Drug Choice: The Latest Advances in Wet AMD TherapyArshad M. Khanani, MD, MA; Lejla Vajzovic, MD, and Joseph M. Coney, MD
09.10.21
The Art of Drug Choice: International Panel in Wet AMD: Safety DataArshad M. Khanani, MD; Justus G. Garweg, MD; Seenu M. Hariprasad, MD; Peter Kertes, MD, FRCSC
09.01.21
The Art of Drug Choice: International Panel in Wet AMD: The PipelineArshad M. Khanani, MD; Justus G. Garweg, MD; Seenu M. Hariprasad, MD; Peter Kertes, MD, FRCSC
08.20.21
The Art of Drug Choice: International Panel in Wet AMD: Phase 3 and Real-World Data to WatchArshad Khanani, MD, MA; Justus Garweg, MD; Seenu Hariprasad, MD; Peter Kertes, MD, FRCSC
08.06.21
The Art of Drug Choice: International Panel in Wet AMD: When and Why Switching Therapy Makes SenseArshad M. Khanani, MD, MA; Justus G. Garweg, MD; Seenu M. Hariprasad, MD; and Peter Kertes, MD, FRCSC
11.19.20
The Art of Drug Choice: Safety in Wet AMDArshad M. Khanani, MD, MA; Christopher G. Fuller, MD; Nikolas J.S. London, MD, FACS; and Christina Y. Weng, MD, MBA
11.19.20
The Art of Drug Choice: Wet AMD PipelineArshad M. Khanani, MD, MA; Christopher G. Fuller, MD; Nikolas J.S. London, MD, FACS; and Christina Y. Weng, MD, MBA
11.19.20
The Art of Drug Choice: Phase 3 Trials in Wet AMDArshad M. Khanani, MD, MA; Christopher G. Fuller, MD; Nikolas J.S. London, MD, FACS; and Christina Y. Weng, MD, MBA
